drugset / Trial / NCT06292689
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
Phase 2
Recruiting
40 enrolled
Zhejiang Cancer Hospital
Akeso · collabInnovent Biologics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of cardunolizumab in combination with/without chemotherapy ± bevacizumab for recurrent or metastatic vulvar and vaginal cancers that are not amenable to radical treatment.
Timeline
- Start
- 2024-03-22
- Primary completion
- 2026-03-22
- Completion
- 2027-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cardunolizumab | Unknown | 10 mg/kg | — |